Patterns of cortical thinning in different subgroups of schizophrenia
Igor Nenadic, Rachel A. Yotter, Heinrich Sauer and Christian Gaser

Background
Alterations of cortical thickness have been shown in imaging studies of schizophrenia but it is unclear to what extent they are related to disease phenotype (including symptom profile) or other aspects such as genetic liability, disease onset and disease progression.

Aims
To test the hypothesis that cortical thinning would vary across different subgroups of patients with chronic schizophrenia, delineated according to their symptom profiles.

Method
We compared high-resolution magnetic resonance imaging data of 87 patients with DSM-IV schizophrenia with 108 controls to detect changes in cortical thickness across the entire brain (P < 0.05, false discovery rate-adjusted). The patient group was divided into three subgroups, consisting of patients with predominantly negative, disorganised or paranoid symptoms.

Results
The negative symptoms subgroup showed the most extensive cortical thinning, whereas thinning in the other subgroups was focused in prefrontal and temporal cortical subregions.

Conclusions
Our findings support growing evidence of potential subtypes of schizophrenia that have different brain structural deficit profiles.

Analysis of cortical thinning from high-resolution magnetic resonance imaging (MRI) scans has contributed to a better understanding of cortical morphological effects of schizophrenia on the brain. Initial studies of people with mostly chronic schizophrenia demonstrated inferior and medial frontal as well as inferior and medial temporal cortical thinning and several subsequent studies have confirmed cortical thinning in frontal and temporal areas to varying degrees; this has included first-episode2–5 as well as chronic patient groups.4,8–10 Several subsequent imaging studies on cortical thickness have suggested that both genetic factors and those related to progressive components in the disorder might have an impact on cortical thinning. Studies in siblings or relatives of patients have produced mixed results, with some suggesting cortical thinning in temporal and/or frontal areas,4,8–10 and others not supporting this finding.11,12 However, several studies have now reported associations of cortical thinning with specific schizophrenia risk genes.13–18 although effect sizes and their ultimate impact on total variability of cortical thickness remains unclear. Studies using other methods for assessment of cortical brain structure, such as voxel-based morphometry (VBM), have recently demonstrated that structural deficits might vary as a function of distinct subtypes of schizophrenia. Two large studies have demonstrated that dividing schizophrenia cohorts into three groups, such that groupings are based on dominant symptoms, reveals patterns of substantial variability in frontal and temporal subregions as well as overlap across groups.19,20 We have also recently replicated this effect of subgroup-related variability in a measure of cortical complexity.21

Regarding, cortical thinning, a recent study has shown effects related to the deficit syndrome of schizophrenia,24 but it remains unclear whether these effects are related to patterns of symptomatology, and thus possibly to a distinct phenotype, or whether it is rather related to intermediate phenotype markers of the disorder. In the present study, we tested the hypothesis that subgroups of patients with schizophrenia, delineated by their symptom profiles, would show different extents of cortical thickness changes, especially in prefrontal and temporal cortical areas. Identifying areas of overlap and divergence would highlight the role of cortical thickness as a putative intermediate phenotype.23 In order to compare cortical thickness with other markers, we used the same approach for subdividing patients with schizophrenia as used in previous VBM studies.19,20

Method
We studied a cohort of 87 patients with DSM-IV schizophrenia and 108 healthy controls, all of whom had provided written informed consent to a protocol approved by the Ethics Committee of the Medical School of Friedrich-Schiller-University, Jena. All participants were adults and were right-handed.25 The sample was drawn from a slightly larger cohort of 99 patients and 113 healthy controls, for which VBM analyses were presented previously,20 and identical to a sample in a recent analysis of a novel cortical complexity measure.21 Although all of the initial patients and controls passed the VBM quality control protocol, 12 participants had to be excluded based on our quality control protocol for cortical surface-based measures.

Participants
We studied a cohort of 87 patients with DSM-IV schizophrenia and 108 healthy controls, all of whom had provided written informed consent to a protocol approved by the Ethics Committee of the Medical School of Friedrich-Schiller-University, Jena. All participants were adults and were right-handed. The sample was drawn from a slightly larger cohort of 99 patients and 113 healthy controls, for which VBM analyses were presented previously,20 and identical to a sample in a recent analysis of a novel cortical complexity measure.21 Although all of the initial patients and controls passed the VBM quality control protocol, 12 participants had to be excluded based on our quality control protocol for cortical surface-based measures.

Patients were recruited from in-patient and out-patient facilities of the Jena University Hospital's Department of Psychiatry, and underwent diagnostic assessment by a psychiatrist, who also rated the severity of positive and negative symptoms on the Scale for Assessment of Positive Symptoms (SAPS)23 and Scale for Assessment of Negative Symptoms (SANS)26 respectively at the time of scanning (same week). All patients were on stable antipsychotic medication. Healthy controls had no concurrent or previous psychiatric disorder, nor major medical or neurological conditions.

Both the SANS and SAPS scores (using single items) were used to derive a delineation of three subgroups based on factor analysis with Promax rotation. Delineation was based on the larger initial sample of 99 patients and 113 healthy controls. The three-subgroup
The subgroups consisted of: (a) 31 participants with predominantly negative symptoms (negative symptoms subgroup; 16 female, 15 male; mean age 35.54 years, s.d. = 11.17); (b) 23 participants with predominantly disorganised symptoms (disorganised symptoms subgroup; 9 female, 14 male; mean age 35.39 years, s.d. = 11.13); and (c) 33 participants with predominantly paranoid symptoms (paranoid symptoms subgroup; 14 female, 19 male; mean age 35.54 years, s.d. = 11.18). These subgroups did not differ significantly from the control group (40 females, 68 males; mean age 32.16 years, s.d. = 9.99) in age or gender (t-tests for age: control group v. negative symptoms subgroup, \( P = 0.135 \); control group v. disorganised symptoms subgroup, \( P = 0.209 \); control group v. paranoid symptoms subgroup, \( P = 0.126 \); \( \chi^2 \) for gender: control group v. negative symptoms subgroup, \( P = 0.145 \); control group v. disorganised symptoms subgroup, \( P = 0.852 \); control group v. paranoid symptoms subgroup, \( P = 0.578 \)).

Psychopathology scores for the three subgroups, as reported previously,\(^{21} \) were as follows. Negative symptoms subgroup: SAPS mean 11.5 (s.d. = 11.7), SANS mean 44.6 (s.d. = 14.1); disorganised symptoms subgroup: SAPS mean 24.3 (s.d. = 14.0), SANS mean 35.7 (s.d. = 16.5); paranoid symptoms subgroup: SAPS mean 22.6 (s.d. = 18.9), SANS mean 27.8 (s.d. = 17.8). Also, there was no difference between subgroups for disease duration (negative symptoms subgroup: mean 8.07 years, s.d. = 8.11; disorganised symptoms subgroup: mean 10.14 years, s.d. = 7.68; paranoid symptoms subgroup: mean 7.29 years, s.d. = 7.44; ANOVA not significant) or age at onset (negative symptoms subgroup: mean 28.25 years, s.d. = 9.27; disorganised symptoms subgroup: mean 26.13 years, s.d. = 11.6; paranoid symptoms subgroup: mean 30.23 years, s.d. = 9.82; ANOVA not significant).

### Results

**Schizophrenia subgroups**

Before their removal in DSM-5,\(^{33} \) clinical subtypes of schizophrenia have been a consistent feature of diagnostic classification; however, their application in biological research has seen gradual decline.\(^{13,34} \) This is at odds with the widely accepted notion that the (wider) schizophrenia definition most likely encompasses several biologically distinct disease entities. Identification of putative biological markers for schizophrenia will therefore have to consider not only variability introduced by general factors (such as disease onset, disease severity and so on), but also whether this marker relates to a common deficit or to a pathophysiological feature expressed in varying degrees across subgroups.

In this study, we provide evidence that regional variability of cortical thinning in schizophrenia is related to symptom profiles and distinct subgroups. Our findings add to an increasing body of evidence that regional variability of cortical thinning in schizophrenia is related to symptom profiles and distinct subgroups.

#### Discussion

**Table 1** Global (hemisphere) analysis of cortical thickness for control and schizophrenia groups

<table>
<thead>
<tr>
<th></th>
<th>Cortical thickness, mm: mean (SEM)</th>
<th>( P^a )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy control group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left hemisphere</td>
<td>2.4676 (0.0009)</td>
<td></td>
</tr>
<tr>
<td>Right hemisphere</td>
<td>2.4621 (0.0009)</td>
<td></td>
</tr>
<tr>
<td>Schizophrenia group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left hemisphere</td>
<td>2.3752 (0.0014)</td>
<td>1.0 ( \times 10^{-6} )</td>
</tr>
<tr>
<td>Right hemisphere</td>
<td>2.3773 (0.0014)</td>
<td>2.4 ( \times 10^{-7} )</td>
</tr>
<tr>
<td>Negative symptoms subgroup</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left hemisphere</td>
<td>2.3420 (0.0040)</td>
<td>2.0 ( \times 10^{-6} )</td>
</tr>
<tr>
<td>Right hemisphere</td>
<td>2.3495 (0.0043)</td>
<td>6.5 ( \times 10^{-7} )</td>
</tr>
<tr>
<td>Disorganised symptoms subgroup</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left hemisphere</td>
<td>2.3925 (0.0045)</td>
<td>0.001</td>
</tr>
<tr>
<td>Right hemisphere</td>
<td>2.3911 (0.0045)</td>
<td>0.003</td>
</tr>
<tr>
<td>Paranoid symptoms subgroup</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left hemisphere</td>
<td>2.3941 (0.0037)</td>
<td>0.0004</td>
</tr>
<tr>
<td>Right hemisphere</td>
<td>2.3940 (0.0038)</td>
<td>0.002</td>
</tr>
</tbody>
</table>

\( \text{SEM, standard error of the mean.} \)

\( a. \) Comparison with the control group.

Patients with schizophrenia showed cortical thinning on global (hemispheric), regional and vertex-wise levels. Cortical thinning was evident across both left and right hemispheres, and was highly significant (Table 1). The effect was most pronounced for the negative symptoms subgroup.

Our main analysis of regional effects across the three subgroups (Table 2) showed that the negative symptoms subgroup showed significant cortical thinning (\( P<0.05, \) FDR-adjusted) in prefrontal and temporal areas, as well as almost all other parietal and occipital cortical regions. The paranoid symptoms subgroup also showed significant thinning across several prefrontal and temporal areas, with sparing of the temporopolar, frontopolar and bilateral cuneus, whereas effects in inferior temporal and superior parietal areas varied across hemispheres. The disorganised symptoms subgroup showed the least cortical thinning, but still revealed several significantly thinner regions, including the superior and middle prefrontal, as well as temporal cortices.

Vertex-wise analyses showed a similar pattern, with the negative symptoms subgroup showing the most extensive deficits (Fig. 1). Regions of overlap of the three subgroups included left superior and inferior frontal, right superior temporal cortical areas.
of research highlighting the biological heterogeneity of schizophrenia, which could provide important hints to delineating universal v. specific pathological pathways.22,35

Recent studies have established that regional cortical thinning is not only present at disease onset in schizophrenia, but also is evident in high-risk individuals in some areas.1 In addition, several recent studies have addressed the influence of certain clinical factors of disease and genetic risk on cortical thinning in schizophrenia.16,18,36 Yang et al demonstrated that cortical thinning might also be observed in non-psychotic relatives of people with schizophrenia, although those with the disease had more pronounced thinning, especially in frontal and temporal areas.15 Although this establishes both alterations related to disease liability or general phenotypic variation, there is rather little data on the heterogeneity of cortical thickness within participant groups with schizophrenia that would reflect possible subgroups within the disease entity. There is recent evidence of an association between the deficit subtype of schizophrenia and regional cortical thinning, but the results have been mixed. Whereas one found a significant difference in anterior cingulate thickness and volume,12 another study found mostly overlapping regional thinning in patients with and without deficits compared with a control group.23 Therefore, cortical thickness may be unable to separate those subtypes, albeit other morphometric markers did diverge.

Compared with the subtypes used in our study, the deficit syndrome relies mostly on outcome, i.e. longitudinal aspects. Although this might result in higher temporal stability of phenotype, it has not utilised prototypes or assignment to a subgrouping, it remains to be clarified whether the deficit subtype truly correlates with a distinct biological endophenotype or merely insufficiently supported by (biological) research.13 Although our studies have been based on clinical prototypes rather than biological parameters. Their validity on biological grounds has been insufficiently supported by (biological) research.13 Although our approach has also been based on psychopathology as a clinical phenotype, it has not utilised prototypes or assignment to a
Nenadic et al

subgroup by clinical decision, but rather has used psychometric aspects of symptom ratings to develop a more stable clinical phenotype, which is less susceptible to clinical rating biases.

Differences in our findings between subgroups

The regional patterns in frontal, temporal and cingulate areas across our three subsamples merit some attention. Our findings in the negative symptoms subgroup most closely resemble a pattern of widespread cortical thinning, almost lacking regional specificity, as seen in some recent large samples. Probably the greatest overlap between our three subgroups was seen in prefrontal regions, where all three groups showed convergence in areas covering both the orbitofrontal cortices (except left medial orbitofrontal cortex for the disorganised symptoms subgroup, which did not reach significance), superior and rostral middle frontal (again, except left superior frontal cortex for the disorganised symptoms subgroup) and right frontal pole regions. In contrast, temporal areas, such as the temporal pole, fusiform cortex and even superior temporal showed less convergence, as none of these areas showed thinning across all three groups. This was also the case for the medial temporal areas (parahippocampal and entorhinal). Our study did not include a detailed analysis of hippocampal thickness, which requires other analytical approaches to address the more convoluted topography.

Considering the three subgroups in terms of how many regions showed reduction of cortical thickness, it is noteworthy that the disorganised symptoms subgroup showed the least deficits, which is consistent with recent VBM studies, where the extent of deficits was also smallest in this subgroup. Overall, the pattern of the negative symptoms subgroup showing the most widespread pathology is consistent with our previous study assessing cortical complexity, although cortical complexity variation (both reduction and increase) in the negative symptoms subgroup was not as widespread and extensive as the cortical thickness deficit.

Limitations

The study has some limitations. Given that this is a cross-sectional study with patients well past their first episode, the effects of disease progression, which might diverge between subgroups, cannot be controlled for. Subgroups might also have varied disease severity, which is difficult to assess, especially in the absence of unequivocal unidimensional markers. This is also the case for antipsychotic medication, which might at least have some subtle effects on cortical thickness (including frontal areas), although recent studies in psychosis are not suggestive of very strong effects and actually demonstrate some reversibility of cortical thinning during short-term treatment. In participants with chronic schizophrenia, cumulative intake of antipsychotics is often difficult to assess, and given potential non-adherence to treatment, is also difficult to assess retrospectively. Chlorpromazine equivalents, which are often used in clinical studies to calculate simple dose equivalents between different antipsychotics, are often not to be useful for this type of study, since brain structural effects of antipsychotics are probably not only related to dopamine D2 receptor occupancy or other pharmacological factors important for assessment of clinical efficacy. Finally, we also cannot rule out effects of alcohol intake or illicit substances. These effects are difficult to track, especially when assessed retrospectively.

Implications

We conclude from our findings, that although cortical thickness is reduced in schizophrenia across multiple areas, especially the prefrontal cortex, the spatial extent and effect size are variable.

Fig. 1 Vertex-wise analysis (P<0.05, false discovery rate-adjusted) of cortical thickness and statistical comparison (v. control group) of the entire schizophrenia group (left column), the negative symptoms subgroup (second column), disorganised symptoms subgroup (third column) and paranoid symptoms subgroup (last column).
across subgroups delineated by predominant symptoms. Our results warrant further exploration of the notion that different patterns of regional thinning might be related to different biological subtypes, which might then be used as different intermediate phenotypes for the dissociation of genetically distinct forms of the disease.

Igor Nenadic, MD, Department of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany; Rachel A. Yotter, PhD, Department of Psychiatry and Psychotherapy, University Hospital Jena, Jena, Germany, and Section of Biomedical Image Analysis, University of Pennsylvania, Philadelphia, USA; Heinrich Sauer, MD, Department of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany; Christian Gaser, PhD, Department of Psychiatry and Psychotherapy and Department of Neurology, Jena University Hospital, Jena, Germany

Correspondence: Igor Nenadic, Department of Psychiatry and Psychotherapy, Jena University Hospital, Philosophenweg 3, 07743 Jena, Germany. Email: igor.nenadic@uni-jena.de

First received 18 Mar 2014, final revision 4 Jun 2014, accepted 29 Sep 2014

Funding

This study was supported by grants from the Friedrich-Schiller-University of Jena (DRM 21007087 to I.N.) and the BMF (BMBF 01EV0709 and BMBF01GQ0740 to C.G.).

References


30 Fischl B, Sereno MI, Tootell RB, Dale AM. High-resolution intersubject averaging and a coordinate system for the cortical surface. Hum Brain Mapp 1999; 8: 272–84.
37 Nenadic I, Sauer H, Smesny S, Gaser C. Aging effects on regional brain structural changes in schizophrenia. Schizophr Bull 2012; 38: 838–44.